Cour Pharmaceuticals, a Chicago, IL-based clinical-stage biotechnology company developing novel immune-modifying nanoparticles (COUR NanoParticles or CNPs) designed to reprogram the immune system in treating autoimmune disorders, raised $30M in funding.
The round was led by Alpha Wave Ventures. As part of the financing, Chris Dimitropoulos, Managing Director, Biotechnology at Alpha Wave Global, will join COUR’s Board of Directors.
The company intends to use the funds to expand its CNP platform technology and advance its two human proof-of-concept studies in Primary Biliary Cholangitis and Peanut allergy, as well as development programs in Myasthenia Gravis and Type 1 Diabetes.
Led by CEO John J. Puisis, Cour Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. Its platform of immune-modifying nanoparticles focus on treating the root cause of immune disease, unlike traditional approaches, which only minimize symptoms using toxic immune suppression.
The underlying technology was acquired from Northwestern University and draws from more than 30 years of research in immune tolerance.
FinSMEs
07/09/2022